Lion Biotechnologies to Present New Interim Data

Lion Biotechnologies to Present New Interim Data

Lion Biotechnologies (LBIO) said early Thursday it plans to present new interim data from the first cohort of its ongoing phase 2 study of LN-144 for the treatment of metastatic melanoma at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago next month. The data is from nine patients in cohort one who were infused as of Jan. 31. These advanced metastatic melanoma patients are a […]

Read More ˃
Health Care Stocks Lower

Health Care Stocks Lower

Health care stocks were mostly lower Tuesday, with the NYSE Health Care Index falling almost 0.4% while shares of health care companies in the S&P 500 were down more than 0.5% as a group. In company news, Mirna Therapeutics (MIRN) slumped Tuesday, with shares of the medical device manufacturer at one point today falling more than 31% to a session low of $1.40 a share after today announcing plans to […]

Read More ˃
Cancer Genetics Partners With Roche Unit

Cancer Genetics Partners With Roche Unit

Cancer Genetics, an oncology diagnostics company, said Monday it has partnered with Ventana Medical Systems, a member of Switzerland’s Roche Group, to provide access to a newly-approved predictive biomarker test for new immuno-oncology therapy for advanced bladder cancer. Cancer Genetics said will work to enable rapid patient access to the test following the U.S. Food and Drug Administration’s approval of Roche’s VENTANA PD-L1. CGI participated in a new program launched […]

Read More ˃
uniQure Presents Data

uniQure Presents Data

uniQure N.V, a gene therapy company, presented data on successful repeated hepatic gene delivery with its AAV5 vector, following a proprietary immunoadsorption procedure in non-human primates (NHPs). This immune-adsorption procedure shows promising pre-clinical outcomes which can potentially become a successful strategy for readministration of a gene therapy in a therapeutic regimen, the company said in a press release Thursday. The results describing successful sequential transduction with the two reporter transgenes […]

Read More ˃
Portola Pharma Shares Rise

Portola Pharma Shares Rise

Portola Pharmaceuticals shares surged more than 11% intraday, touching their highest level since January 2016, after the company reported late Monday a Q1 loss of $0.74 per diluted share compared with a loss of $1.15 per share a year ago, beating the $0.81 average loss-per-share estimate from analysts polled by Capital IQ. Total revenue slumped to $5.1 million from $8.3 million a year ago, but still coming in above the […]

Read More ˃
Cambrex Shares Touch New Record

Cambrex Shares Touch New Record

Cambrex shares rose to a new record on Thursday after the provider of products and services for the development and commercialization of generic therapeutics reported Q1 adjusted income of $0.68 per share compared to $0.50 a year ago and well above the $0.48 average estimate from analysts polled by Capital IQ. CBM was 2% higher at $57.48 recently, trading in a new 52-week range between $38.30 and $62.95. Revenue rose […]

Read More ˃
Martin Marietta Materials Q1 Results Top Views

Martin Marietta Materials Q1 Results Top Views

Martin Marietta Materials shares were up almost 4% pre-market Tuesday after the supplier of aggregates products used for construction reported Q1 earnings per diluted share of $0.67, down from $0.69 for the year-ago quarter, but easily beating the Capital IQ consensus forecast of $0.47. Net sales for the quarter were $791.7 million, up from $734 million for the same period last year, and ahead of the analyst forecast of $729.3 […]

Read More ˃
Camber Energy Starts Cost-Cutting Initiatives

Camber Energy Starts Cost-Cutting Initiatives

Camber Energy gained early Friday after the oil and gas company said it has started cost-cutting initiatives to significantly reduce overall general and administrative costs. Shares were up 9% at $0.39 per share in early Friday trading. Since the closing of the Segundo deal last August, Camber has incurred professional fees in addition to increased staffing costs that have exceeded one of the restrictive covenants in its existing loan agreement […]

Read More ˃
ArQule Gets U.S. Patent

ArQule Gets U.S. Patent

ArQule said pre-market Wednesday that the U.S. Patent and Trademark Office has issued U.S. Patent on composition of matter of ARQ 531. ArQule will be entitled to patent protection through December 2035 in the U.S. for the allowed claims. ARQ 531 is an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). The company plans to begin a phase 1 clinical trial […]

Read More ˃